Concord Biotech Limited will host a group meeting for analysts and institutional investors on August 26, 2026, in Ahmedabad.

The interaction is scheduled from 1:00 pm to 3:00 pm and will be organized by Phillip Capital PCG. Company officials will participate in the session to address queries from market participants.

Meeting Details

The company disclosed that discussions will be strictly based on publicly available information. No unpublished price-sensitive information (UPSI) is intended to be shared during the interactions.

This intimation was issued pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015. The notice was signed by Paritosh Trivedi, Company Secretary & Compliance Officer, on August 21, 2026.

The company noted that changes to the schedule may occur due to exigencies on the part of participants or the company.

Concord Biotech Limited reported a robust start to fiscal year 2027, with Q1 FY27 revenues rising 26% year-on-year to ₹257 crore, driven by strong demand in its active pharmaceutical ingredients (API) segment and significant export growth. The Ahmedabad-based biopharmaceutical company posted a profit after tax (PAT) of ₹58 crore, up 31% from ₹44.4 crore in the corresponding quarter of the previous year. This performance marks a recovery from the headwinds faced in FY26, including regulatory delays and shifting customer procurement patterns, signaling renewed momentum in both domestic and international markets.

The financial results were disclosed following an earnings call held on August 3, 2026, with the transcript submitted to stock exchanges on August 7, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Joint Managing Director and CEO Ankur Vaid highlighted that the growth was broad-based across key product categories, including immunosuppressants, anti-infectives, oncology, and antifungals, rather than being dependent on a single segment. The company remains debt-free, holding cash and cash equivalents of over ₹442 crore as of June 30, 2026.

Financial Performance Highlights

*Note: Previous year figures derived from stated growth percentages.

Revenue from the API segment surged 42% to ₹219 crore, offsetting a 23% decline in formulation revenue, which stood at ₹39 crore. Management attributed the formulation dip primarily to the absence of Middle East tender supplies recorded in the prior year, noting that underlying domestic business grew by double digits when adjusted for this one-off factor. Export revenues grew by 46% year-on-year, reflecting increased inquiries from regulated and semi-regulated markets in Europe, Japan, and Latin America.

Operational Updates and Pipeline

The company secured Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration for mycophenolate mofetil and Tofacitinib tablets during the quarter. These approvals, combined with successful inspections by ANVISA in Brazil and PPB in Kenya, expand Concord’s addressable market. The injectable facility at Limbasi commenced commercial operations, though capacity utilization remained low at approximately 5% as the company focuses on domestic sales and customer audits before scaling up exports.

What the Numbers Show

The divergence between API and formulation performance underscores Concord’s strategic pivot toward high-margin fermentation-based APIs. While formulation revenue contracted, the 42% growth in API sales drove overall top-line expansion and margin improvement. The gross margin increase of 100 basis points to 78.9% reflects strong pricing discipline and favorable product mix. With EBITDA margins expanding by 190 basis points to 32%, the company is leveraging its scale advantages in fermentation technology to capture wallet share from competitors, particularly in anti-infective and oncology segments where new products like Nystatin and Fusidic Acid are gaining traction.

Looking ahead, management expects to sustain growth rates better than historical averages, supported by a pipeline of 2-3 new product launches annually. The company aims to utilize its existing infrastructure to reach ₹3,000 crore in revenue within five to six years, with approximately ₹2,200 crore projected from APIs and ₹600-700 crore from formulations. Capital expenditure for the quarter was modest at ₹9.5 crore, preserving the company’s net cash position for potential organic or inorganic growth opportunities in fermentation adjacencies.